Many thxs to $ONCS CMO Dr. Pierce for making this happen in his protocol meetings with the FDA/DSMB. It is the only way it could have materialized as he is thoroughly familiar with PD-I/PDL-1 as a lead investigator with Merck's Clinical Melanoma program!